-
Views
-
Cite
Cite
Moderated Poster Session 2: Sunday, 21 October 2012 - 14:00 - 18:00, European Heart Journal. Acute Cardiovascular Care, Volume 1, Issue 1_suppl, 1 October 2012, Pages 56–59, https://doi.org/10.1177/2048872612461726d
- Share Icon Share
Extract
185 High-dose statin therapy and the clinical effect of resistance to antiplatelet therapy in acute coronary syndrome
I I Vorobyeva, A V Shpektor, E U Vasilieva
Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
Purpose
The aim of this study was to determine whether there is an association between antiplatelet therapy resistance and systemic inflammation in patients with acute coronary syndrome (ACS).
Methods
We included 122 patients with ACS hospitalized at Moscow City Hospital. We measured platelet function using simultaneous light transmittance aggregometry (spontaneous aggregation and ADP-induced), Thromboelastography Platelet Mapping (TEG-PM), and VerifyNow Aspirin and P2Y12 assays. The following markers of systemic inflammation were estimated: white blood cell count and plasma levels of hs-CRP, sCD40L, sP-selectin, fibrinogen. All patients received aspirin at 250–325 mg and a loading dose of clopidogrel (300–600 mg) on arrival, followed by 125 mg of aspirin and 75 mg of clopidogrel per day. For the following analysis, the patients were separated into two groups. Both groups received atorvastatin: one group at 20 mg per day (N = 18) and the second at 80 mg per day (N = 24) for at least 7 days.
Comments